1.90
+0.05(+2.70%)
Currency In USD
Address
3545 John Hopkins Court
San Diego, CA 92121
United States of America
Phone
858 731 8389
Website
Sector
Healthcare
Industry
Biotechnology
Employees
56
First IPO Date
May 07, 2015
| Name | Title | Pay | Year Born |
| Dr. Sanjay S. Shukla M.D., M.S. | President, Chief Executive Officer & Director | 768,184 | 1972 |
| Dr. David J. King Ph.D. | Scientific Consultant | 327,312 | 1959 |
| Ms. Nancy E. Denyes Krueger | General Counsel & Corporate Secretary | 518,199 | 1968 |
| Ms. Jill M. Broadfoot | Chief Financial Officer | 544,753 | 1962 |
| Ms. Ashlee Dunston | Director of Investor Relations & Corporate Communications | 0 | N/A |
| Dr. Leslie Nangle Ph.D. | Vice President of Research | 0 | N/A |
| Xiang-Lei Yang Ph.D. | Founder | 0 | N/A |
| Mr. Peter Villiger | Vice President of Corporate Development | 0 | N/A |
| Dr. Ying J. Buechler Ph.D. | Executive Director of Biologics Development & Manufacturing | 0 | N/A |
| Ms. Danielle Campbell | Vice President of Human Resource | 0 | N/A |
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.